Telo Genomics Corp. (TDSGF)
USD 0.06
(-0.34%)
USD 0.06
(-0.34%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 312.86 Thousand CAD | 35.99% |
| 2022 | 230.07 Thousand CAD | 49.73% |
| 2021 | 153.65 Thousand CAD | -60.94% |
| 2020 | 393.41 Thousand CAD | -69.91% |
| 2019 | 1.3 Million CAD | 75.85% |
| 2018 | 743.53 Thousand CAD | -16.1% |
| 2017 | 886.25 Thousand CAD | 2441.66% |
| 2016 | 34.86 Thousand CAD | 113.93% |
| 2015 | 16.29 Thousand CAD | -2.16% |
| 2014 | 16.65 Thousand CAD | 22.43% |
| 2013 | 13.6 Thousand CAD | -20.76% |
| 2012 | 17.17 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 257.04 Thousand CAD | -20.01% |
| 2024 Q2 | 321.35 Thousand CAD | 45.32% |
| 2024 Q1 | 221.14 Thousand CAD | -29.32% |
| 2023 Q1 | 207.14 Thousand CAD | -9.97% |
| 2023 Q2 | 141.13 Thousand CAD | -31.87% |
| 2023 Q3 | 163.76 Thousand CAD | 16.04% |
| 2023 FY | 312.86 Thousand CAD | 35.99% |
| 2023 Q4 | 312.86 Thousand CAD | 91.04% |
| 2022 Q3 | 87.56 Thousand CAD | 11.94% |
| 2022 FY | 230.07 Thousand CAD | 49.73% |
| 2022 Q1 | 205.88 Thousand CAD | 33.99% |
| 2022 Q2 | 78.22 Thousand CAD | -62.01% |
| 2022 Q4 | 230.07 Thousand CAD | 162.75% |
| 2021 FY | 153.65 Thousand CAD | -60.94% |
| 2021 Q1 | 282.23 Thousand CAD | -28.26% |
| 2021 Q2 | 228.46 Thousand CAD | -19.05% |
| 2021 Q3 | 200.72 Thousand CAD | -12.14% |
| 2021 Q4 | 153.65 Thousand CAD | -23.45% |
| 2020 Q3 | 260.44 Thousand CAD | -47.49% |
| 2020 FY | 393.41 Thousand CAD | -69.91% |
| 2020 Q2 | 496 Thousand CAD | -69.44% |
| 2020 Q1 | 1.62 Million CAD | 24.13% |
| 2020 Q4 | 393.41 Thousand CAD | 51.06% |
| 2019 FY | 1.3 Million CAD | 75.85% |
| 2019 Q3 | 1.16 Million CAD | 10.94% |
| 2019 Q2 | 1.05 Million CAD | 5.16% |
| 2019 Q4 | 1.3 Million CAD | 12.23% |
| 2019 Q1 | 998.56 Thousand CAD | 34.3% |
| 2018 Q1 | 869.4 Thousand CAD | -1.9% |
| 2018 FY | 743.53 Thousand CAD | -16.1% |
| 2018 Q4 | 743.53 Thousand CAD | -9.51% |
| 2018 Q3 | 821.71 Thousand CAD | -30.54% |
| 2018 Q2 | 1.18 Million CAD | 36.06% |
| 2017 Q2 | 318.74 Thousand CAD | -52.36% |
| 2017 Q4 | 886.25 Thousand CAD | 38.83% |
| 2017 Q1 | 669.11 Thousand CAD | 8447.69% |
| 2017 FY | 886.25 Thousand CAD | 2441.66% |
| 2017 Q3 | 638.35 Thousand CAD | 100.27% |
| 2016 Q3 | 35.96 Thousand CAD | 3.15% |
| 2016 Q2 | 34.86 Thousand CAD | 800.77% |
| 2016 Q4 | 7828.00 CAD | -78.23% |
| 2016 FY | 34.86 Thousand CAD | 113.93% |
| 2016 Q1 | 3871.00 CAD | -32.77% |
| 2015 Q4 | 5758.00 CAD | -66.71% |
| 2015 Q2 | 16.29 Thousand CAD | 427.31% |
| 2015 Q3 | 17.29 Thousand CAD | 6.14% |
| 2015 FY | 16.29 Thousand CAD | -2.16% |
| 2015 Q1 | 3091.00 CAD | -46.39% |
| 2014 Q3 | 26.37 Thousand CAD | 58.36% |
| 2014 FY | 16.65 Thousand CAD | 22.43% |
| 2014 Q1 | 1780.00 CAD | -60.04% |
| 2014 Q4 | 5766.00 CAD | -78.14% |
| 2014 Q2 | 16.65 Thousand CAD | 835.84% |
| 2013 Q3 | 17.92 Thousand CAD | 31.76% |
| 2013 Q1 | 1797.00 CAD | -88.2% |
| 2013 Q2 | 13.6 Thousand CAD | 657.15% |
| 2013 FY | 13.6 Thousand CAD | -20.76% |
| 2013 Q4 | 4455.00 CAD | -75.15% |
| 2012 Q4 | 15.22 Thousand CAD | 98.33% |
| 2012 FY | 17.17 Thousand CAD | 0.0% |
| 2012 Q3 | 7676.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | 91.328% |
| Arrayit Corporation | 7.49 Million USD | 95.827% |
| Atlantic International Corp. | 3.82 Million USD | 91.828% |
| Biocept, Inc. | 22.01 Million USD | 98.579% |
| Bioqual, Inc. | 18.93 Million USD | 98.348% |
| CardioGenics Holdings Inc | 1.79 Million USD | 82.569% |
| DermTech, Inc. | 64.75 Million USD | 99.517% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 99.957% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 97.474% |
| iMD Companies, Inc. | 1.67 Million USD | 81.313% |
| IDenta Corp. | 1.01 Million USD | 69.119% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 98.889% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -5.008% |
| InVitro International | 78.99 Thousand USD | -296.087% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 98.414% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -141.977% |
| Medical Imaging Corp. | 9.51 Million USD | 96.713% |
| NovelStem International Corp. | 4.2 Million USD | 92.562% |
| Optigenex Inc. | 9.57 Million USD | 96.731% |
| PharmChem, Inc. | 558.64 Thousand USD | 43.995% |
| Proteome Sciences plc | 18.48 Million USD | 98.308% |
| Response Genetics, Inc | 15.86 Million USD | 98.028% |
| Rennova Health, Inc. | 49.66 Million USD | 99.37% |
| RushNet, Inc. | 6.23 Million USD | 94.985% |
| ScreenPro Security Inc. | 1.6 Million USD | 80.453% |
| Stella Diagnostics Inc. | 18 Million USD | 98.262% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | 96.186% |
| Todos Medical Ltd. | 50.15 Million USD | 99.376% |